APF530 versus ondansetron, each in a guideline-recommended three-drug regimen, for the prevention of chemotherapy-induced nausea and vomiting due to anthracycline plus cyclophosphamide–based highly emetogenic chemotherapy regimens: a post hoc subgroup analysis of the Phase III randomized MAGIC trial

References

• HilariusDLKloegPHvan der WallEvan den HeuvelJJGundyCMAaronsonNKChemotherapy-induced nausea and vomiting in daily clinical practice: a community hospital-based studySupport Care Cancer201220110711721258948
   PubMed Web of Science ®Google Scholar
• VidallCDielensegerPFarrellCEvidence-based management of chemotherapy-induced nausea and vomiting: a position statement from a European cancer nursing forumEcancermedicalscience2011521122276054
   PubMedGoogle Scholar
• NCCN Clinical Practice Guidelines in Oncology: Antiemesis—v22016 Available from: https://www.nccn.org/professionals/physician_gls/f_guidelines.aspAccessed September 23, 2016
   Google Scholar
• HeskethPJKrisMGGrunbergSMProposal for classifying the acute emetogenicity of cancer chemotherapyJ Clin Oncol19971511031098996130
   PubMed Web of Science ®Google Scholar
• AaproMGrallaRHerrstedtJMolassiotisARoilaFMASCC/ESMO antiemetic guideline 2016 Available from: http://www.mascc.org/antiemetic-guidelinesAccessed September 23, 2016
   Google Scholar
• HeskethPJBohlkeKLymanGHAntiemetics: American Society of Clinical Oncology Focused Guideline UpdateJ Clin Oncol201534438138626527784
   PubMed Web of Science ®Google Scholar
• GrunbergSMDeusonRRMavrosPIncidence of chemotherapy- induced nausea and emesis after modern antiemeticsCancer2004100102261226815139073
   PubMed Web of Science ®Google Scholar
• Van LaarESDesaiJMJatoiAProfessional educational needs for chemotherapy-induced nausea and vomiting (CINV): multinational survey results from 2388 health care providersSupport Care Cancer201523115115725015057
   PubMed Web of Science ®Google Scholar
• BaschEPrestrudAAHeskethPJAntiemetics: American Society of Clinical Oncology clinical practice guideline updateJ Clin Oncol201129314189419821947834
   PubMed Web of Science ®Google Scholar
• GrunbergSMDuganMMussHEffectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapySupport Care Cancer200917558959419037667
   PubMed Web of Science ®Google Scholar
• HuttonBClemonsMMazzarelloSKuchukISkidmoreBNgTIdentifying an optimal antiemetic regimen for patients receiving anthracycline and cyclophosphamide-based chemotherapy for breast cancer—an inspection of the evidence base informing clinical decision-makingCancer Treat Rev2015411095195926442474
   PubMed Web of Science ®Google Scholar
• RoscoeJAMorrowGRColagiuriBInsight in the prediction of chemotherapy-induced nauseaSupport Care Cancer201018786987619701781
   PubMed Web of Science ®Google Scholar
• SchwartzbergLSModianoMRRapoportBLSafety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: a randomised, active-controlled, double-blind, phase 3 trialLancet Oncol20151691071107826272768
   PubMed Web of Science ®Google Scholar
• SekineISegawaYKubotaKSaekiTRisk factors of chemotherapy-induced nausea and vomiting: index for personalized antiemetic prophylaxisCancer Sci2013104671171723480814
   PubMed Web of Science ®Google Scholar
• WarrDGHeskethPJGrallaRJEfficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapyJ Clin Oncol200523122822283015837996
   PubMed Web of Science ®Google Scholar
• Kytril (granisetron) injection, for intravenous use [prescribing information]South San FranciscoGenentech Inc2011 Available from: http://www.gene.com/download/pdf/kytril_injection_prescribing.pdfAccessed September 23, 2016
   Google Scholar
• OttoboniTGelderMO’BoyleEBiochronomer™ technology and the development of APF530, a sustained release formulation of granisetronJ Exp Pharmacol20146152127186139
   PubMedGoogle Scholar
• GabrailNYanagiharaRSpaczynskiMPharmacokinetics, safety, and efficacy of APF530 (extended-release granisetron) in patients receiving moderately or highly emetogenic chemotherapy: results of two phase 2 trialsCancer Manag Res20157839225834466
   PubMed Web of Science ®Google Scholar
• MorrisonDAndersonASlamaMPhase 1 bioavailability study comparing 2 different subcutaneous routes of administration for APF530Support Care Cancer201523Suppl Abstract 11-16-P
   Google Scholar
• RaftopoulosHCooperWO’BoyleEGabrailNBocciaRGrallaRJComparison of an extended-release formulation of granisetron (APF530) versus palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately or highly emetogenic chemotherapy: results of a prospective, randomized, double-blind, noninferiority phase 3 trialSupport Care Cancer201523372373225179689
   PubMed Web of Science ®Google Scholar
• Sustol (granisetron) extended-release injection, for subcutaneous use [prescribing information]Redwood CityHeron Therapeutics2016 Available from: http://www.herontx.com/sustolAccessed September 23, 2016
   Google Scholar
• AaproMSGrunbergSMManikhasGMA phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapyAnn Oncol20061791441144916766588
   PubMed Web of Science ®Google Scholar
• GrunbergSChuaDMaruASingle-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol—EASEJ Clin Oncol201129111495150121383291
   PubMed Web of Science ®Google Scholar
• Zofran (ondansetron hydrochloride) injection for intravenous use [prescribing information]Research Triangle ParkGlaxoSmithKline2014 Available from: http://www.pharma.us.novartis.com/product/pi/pdf/zofran_inj.pdfAccessed September 23, 2016
   Google Scholar
• SchnadigIDAgajanianRDakhilSAPF530 (granisetron injection extended release) in a three drug regimen for delayed CINV in highly emetogenic chemotherapyFuture Oncol201612121469148126997579
   PubMed Web of Science ®Google Scholar
• NCCN Clinical Practice Guidelines in Oncology: Breast Cancer—v12016 Available from: https://www.nccn.org/professionals/physician_gls/f_guidelines.aspAccessed September 23, 2016
   Google Scholar
• GiordanoSHLinYLKuoYFHortobagyiGNGoodwinJSDecline in the use of anthracyclines for breast cancerJ Clin Oncol201230182232223922614988
   PubMed Web of Science ®Google Scholar
• SerrurierKChemotherapy treatment patterns for early stage breast cancer population (ESBC): decreasing use of anthracycline-based regimensJ Clin Oncol201230Suppl 27 Abstract 141
   Web of Science ®Google Scholar
• SiegelRLMillerKDJemalACancer statistics, 2015CA Cancer J Clin201565152925559415
   PubMed Web of Science ®Google Scholar
• GeorgyANeceskasJGoodinSAntiemetic care for patients with breast cancer: focus on drug interactions and safety concernsAm J Health Syst Pharm200764212227223617959573
   PubMed Web of Science ®Google Scholar
• DohertyKMClosing the gap in prophylactic antiemetic therapy: patient factors in calculating the emetogenic potential of chemotherapyClin J Oncol Nurs19993311311910690042
   PubMedGoogle Scholar
• RapoportBLEfficacy of a triple antiemetic regimen with aprepitant for the prevention of chemotherapy-induced nausea and vomiting: effects of gender, age, and regionCurr Med Res Opin20143091875188124911369
   PubMed Web of Science ®Google Scholar
• RapoportBLJordanKBoiceJAAprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind studySupport Care Cancer201018442343119568773
   PubMed Web of Science ®Google Scholar
• Bloechl-DaumBDeusonRRMavrosPHansenMHerrstedtJDelayed nausea and vomiting continue to reduce patients’ quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatmentJ Clin Oncol200624274472447816983116
   PubMed Web of Science ®Google Scholar
• NavariRMPathogenesis-based treatment of chemotherapy-induced nausea and vomiting—two new agentsJ Support Oncol2003128910315352652
   PubMedGoogle Scholar
• NavariRMQinRRuddyKJOlanzapine for the prevention of chemotherapy-induced nausea and vomitingN Engl J Med2016375213414227410922
   PubMed Web of Science ®Google Scholar